Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/16/2022* -- Results Q4 2021 -- -0.83 --
11/12/2021 -- Results Q3 2021 -0.70 -0.91 22.80%
08/13/2021 -- Results Q2 2021 -0.83 -0.71 -17.62%
05/13/2021 -- Results Q1 2021 -0.43 -0.94 54.06%
03/16/2021 -- Results Q4 2020 -0.86 -0.60 -44.41%
11/12/2020 -- Results Q3 2020 -0.63 -0.67 6.11%
08/12/2020 -- Results Q2 2020 -0.57 -0.62 7.73%
05/13/2020 -- Results Q1 2020 -0.42 -0.61 31.15%
*Estimated Date/Time

Earnings

Next Report Date 03/16/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/12/2021
Beat/Miss Upgrade
Return Since -21.20%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
URL https://www.akerotx.com
Investor Relations URL https://ir.akerotx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 16, 2022
Last Earnings Release Nov. 12, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
16.24%
-18.02%
-5.63%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-4.84%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-13.75%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-19.86%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-12.57%
56.85%
-66.70%
-33.39%
-96.85%
-9.48%
-24.44%
-28.93%
-4.08%
As of January 19, 2022.

Profile

Edit
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
URL https://www.akerotx.com
Investor Relations URL https://ir.akerotx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 16, 2022
Last Earnings Release Nov. 12, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
BBC 166395.0 USD 0.67%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits AKRO Tweets